Abdominal subcutaneous fat is a stronger predictor of cardiometabolic risk markers than visceral fat in young lean rural Indians.

Rucha SH. Wagh[1,2], Rupali U. Bawdekar[1], Wareed Alenaini[3], Rashmi B. Prasad[4], Caroline HD. Fall[5], E Louise Thomas[3], Jimmy D Bell[3], Satyajeet P. Khare[2*], Yajnik CS[1*].

[1]Diabetes Unit, King Edward Memorial Hospital and Research Centre, Pune, India.

[2]Symbiosis School of Biological Sciences, Symbiosis International (Deemed) University, Pune, India

[3]Research Centre of Optimal Health, University of Westminster, UK.

[4]Lund University Diabetes Centre, Lund University, Sweden

[5]MRC-Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK

* shared senior authorship

Corresponding Author

Dr Chittaranjan S Yajnik

Diabetes Unit, KEM Hospital and Research Centre,

Rasta Peth, Pune, Maharashtra 411011 India

E-mail ID: csyajnik@gmail.com

Mobile: +91-9822847481

ORCiD: 0000- 0002- 2911- 2378

Word count:
Abstract: 205, Main text: 2712, Tables: 3, Figures: 5 (2 main, 3 supplemental)

Research Insights

What is currently known about this topic? (max. 3 highlights) Indians have higher central obesity (including subcutaneous fat) compared to white Caucasians at similar BMI across the lifecourse. Studies in western population report that visceral fat (VAT) is associated with increased cardiometabolic risk whereas abdominal subcutaneous fat (aSAT) is protective. Studies in native and migrant middle-aged South Asian Indians have exhibited heterogeneity in the associations of VAT and aSAT with cardiometabolic disease. Biopsy studies in migrant Indians have revealed differences in adipocyte morphology in aSAT compared to white Caucasians.
What is the key research question? (formatted as a question) What will be the association of VAT and aSAT with cardiometabolic risk markers in apparently healthy, lean rural young Indian adults?
What is new? (max. 3 highlights) In our study of rural young native Indians, aSAT has a stronger association with cardio-metabolic risk compared to VAT. Our findings suggest that aSAT may have a role in the susceptibility of Indians to higher risk of diabetes and CVD at young age and low BMI
How might this study influence clinical practice? (max. 1 highlight) Abdominal SAT deposition in early life may play a crucial role in increasing the cardiometabolic disease risk in later life, and thereby contribute in early screening, designing interventions (fat loss) and treatments (fat redistribution) to help curb later life NCD risk.

Abstract

Background: Central obesity has been associated with cardiometabolic diseases. Unlike in the white Caucasians, the abdominal subcutaneous adiposity has been associated with higher cardiometabolic risk in Indians. There are few studies in young Indians. We investigated associations of MRI measured abdominal subcutaneous adipose tissue (aSAT) and visceral adipose tissue (VAT) with cardiometabolic risk markers in young lean rural Indian adults.

Methods: We measured aSAT and VAT adiposity by MRI in young adult participants in the PMNS cohort [18yrs, n=590 (310 men)]. We used multiple regression analysis to investigate their associations with a range of cardiometabolic risk markers (glucose-insulin indices, blood pressure, lipids, and inflammatory markers).

Results: In multiple regression models, aSAT was significantly positively associated with 120-min OGTT glucose, insulinogenic index, total cholesterol, triglycerides, leptin, total leukocyte count, CRP and systolic and diastolic blood pressure, and negatively with Matsuda index and

adiponectin. aSAT associations were stronger than VAT for most outcomes. In women, aSAT was associated with all parameters except HDL-cholesterol, whereas in men the associations were similar to those observed in the combined analyses.

Conclusion: In young Indians, aSAT is associated with insulin resistance, dyslipidaemia, and inflammation, unlike in Western populations. Utility of targeting aSAT to prevent cardiometabolic diseases needs to be further investigated.

Key words: Adiposity, South Asian Indian, Lean, Adipose tissue, Abdominal subcutaneous, Visceral

INTRODUCTION

Obesity is a well-known global health burden with an ever-increasing prevalence worldwide (currently 43%). Prevalence is also substantial (23%) in low- or middle-income countries like India which have undergone rapid nutritional transition on the background of multigenerational cycles of undernutrition (1, 2). Obesity is often represented by BMI and other anthropometric measures like waist circumference. Adiposity refers to body fat percentage and is a major consideration in obesity, responsible for increasing risk of cardiometabolic diseases (3). Adiposity is insufficiently captured by BMI and other anthropometric variables. This has led to a change in terminology to 'Adiposity-based Chronic Diseases (ABCD)', which focuses on dysfunction in the mass, distribution and function of adipose tissues (4).

Previous studies in the middle-age Indian population have highlighted the association of central obesity-adiposity (waist circumference, waist hip ratio, truncal skinfolds) with insulin resistance and type 2 diabetes (5). Further, studies have also explored depot-specific associations of abdominal adipose tissue (visceral adipose tissue, VAT vs subcutaneous adipose tissue, aSAT) using imaging techniques with cardiometabolic risk. In western population, VAT has been consistently associated with increased risk of insulin resistance, dyslipidaemia, type 2 diabetes, inflammation, and other cardiometabolic diseases (6); in contrast, aSAT has often been considered metabolically inert or even protective (7). Studies in migrant Indians have suggested adverse associations of aSAT (8). Indian studies exploring such associations have reported variable associations of VAT and aSAT with metabolic dysfunction which may be attributable to differences in age and metabolic status of the population investigated (9-12). In the relatively younger adults, both VAT and aSAT are associated with clinical outcomes whereas in older adults, the associations are limited to VAT.

Based on this evidence, we hypothesize that both aSAT and VAT are associated with cardiometabolic risk markers in young adults. We investigated associations of MRI-measured aSAT and VAT with a range of cardiometabolic risk markers in apparently healthy, relatively lean Indian young adults (18 years of age) in the Pune Maternal Nutrition Study (PMNS), a rural community-based birth cohort.

METHODS

Overview of the Cohort

The PMNS is a preconceptional birth cohort set up in 1993 in six villages around Pune, India (13). Briefly, 2466 married non-pregnant women (F0 generation) were followed-up, and 797 who became pregnant were recruited into the study and delivered live singleton births (F1). Serial data on a range of anthropometric and metabolic parameters is available on the F1 generation. At 18-years, 663 participants (356 men) were followed-up and abdominal MRI was performed in 599 (310 men) (ESM Figure 1).

Measurements at 18-years

Anthropometry measurements

Height, weight, waist, and hip circumferences were measured using standardised methods by trained staff. Body mass index (BMI) was calculated as weight (kg)/(Height (m))^2, WHR was calculated as waist circumference/hip circumference.

MRI measurements

Magnetic Resonance Imaging was performed using a 1.5T Siemens, MAGNETOM Harmony scanner (Siemens corporation, Munich, Germany). Axial 10 mm thick abdominal slices were obtained at 11 mm gap using T1 weighted spin echo sequence with 100-ms repetition time, 7.49ms echo time and one-half excitation for all acquisitions. Three slices were obtained for each acquisition sequence centered at the L4-L5 vertebral disc. The duration of each acquisition

was 36s. All images were analysed using Slice-O-Matic (Tomovision, Montreal, QC, Canada) for abdominal subcutaneous (aSAT) and visceral adipose tissue (VAT) quantification (14) with the area of adipose tissue recorded in cm^2. The aSAT and VAT segmentation method was based on two main tools; image morphology and manual editing to label regions as aSAT or VAT respectively, performed by experts.

Biochemical measurements

Biochemistry measurements included glucose and insulin during an OGTT (glucose load: 75g anhydrous glucose) fasting, and 30- and 120-minutes post-load. Insulin sensitivity was estimated during the OGTT using the Matsuda Index (15). Early insulin secretion was estimated using the insulinogenic index (16). Disposition index (a measure of β cell function adjusted for prevailing insulin sensitivity) was calculated as the product of insulinogenic index and Matsuda index. Triglycerides, HDL, and cholesterol concentrations were also measured using standardised enzymatic assays (Hitachi 902, Roche Diagnostics, GmbH, Germany), LDL-c was measured using the Friedewald equation, we also calculated a ratio of TG:HDL-c as a marker of metabolic dysfunction . Inflammatory markers like leptin and adiponectin were measured using ELISA (Alpco Diagnostics, Salem, NH 03079), c-reactive protein (CRP) was measured by high-sensitivity ELISA (United Biotech. Mountain View, CA, USA).

Definitions

Underweight and overweight/obesity were defined using BMI as per WHO criteria (17). Central obesity was defined as a waist circumference ≥ 0.90 for men and ≥ 0.80 for women. According to ADA 2014 criteria (18), prediabetes was defined based on the OGTT as impaired fasting glucose and/or impaired glucose tolerance (fasting glucose ≥ 100 mg/dl and/or 120min glucose ≥ 140 mg/dl). Dyslipidaemia was defined as triglycerides > 150 mg/dl and/or HDL<40 mg/dL for men and <50 mg/dL for women, and hypertension was defined as blood pressure ≥ 130/85 mm/Hg. Metabolic syndrome was defined as according to IDF criteria (Central obesity

and any two of the following: triglycerides ≥ 150mg/dl; HDL-c < 40 mg/dl in men, < 50 in women; BP ≥ 130/85; fasting plasma glucose ≥ 100) (19).

Statistical analysis

Data are presented as median (25th – 75th percentile). Skewed variables were log transformed. All variables were standardised (mean zero, standard deviation unity) adjusting for age and gender, to enable comparison of effect sizes. The primary analysis was to investigate associations between MRI fat measurements (VAT & aSAT) and other cardio-metabolic risk factors. For this analysis, we performed multiple linear regression models. Furthermore, to compare the coefficients of aSAT and VAT for each outcome, we performed Wald's test presented by Z statistics and p-value. We also performed logistic regression, exploring prediabetes and metabolic syndrome as outcomes.

All statistical analysis was performed using SPSS v26 and R v4.4.1.

RESULTS

Characteristics of participants (Table 1):

Of 663 participants in the 18-year follow-up cohort, abdominal MRI scans were performed for 599 participants, of which 8 scans were excluded due to poor image quality (artefacts and motion-distortions), and 1 female with MODY diabetes. The final analysis included 590 participants (310 men) with complete data (ESM Fig. 1). The median age for the men was 18.2 (17.9-18.6) years and women 17.6 (17.2-18.1) years. Median BMI was 19.0 (17.2, 21.3) kg/m^2 in men and 18.1 (16.8, 20.2) kg/m^2 in women; 41.1% of men and 54.4% of women were underweight; 9.1% of men and 4.3% of women were overweight/obese. Central obesity (waist circumference) was present in 6.1% of men and 5% of women. Forty percent of men and 19.2% of women were glucose intolerant. Men had a greater prevalence of IFG (28.4 % vs 8.5%)

while IGT was more in women (8.2% vs 4.2%). Thirty-two percent of men and 38.4 % of women had dyslipidaemia. None of the participants were hypertensive. A small number (12/590, 2%) could be classified as having metabolic syndrome as per IDF criteria.

MRI data revealed that as a group, the participants had a higher aSAT area (257.8 cm^2) compared to VAT (179.9 cm^2). Women had a higher absolute total abdominal fat area (473.8 cm^2), aSAT area (311.2 cm^2), aSAT-to-VAT ratio (1.9) compared to men, while men had a higher VAT area (194.5 cm^2) (Table 1, ESM Figure 2).

aSAT has stronger associations than VAT with cardiometabolic risk markers

In multiple regression models including both aSAT and VAT as independent variables (adjusted for age and sex), VAT was positively associated with fasting glucose, triglyceride concentrations, systolic blood pressure and inversely with HDL cholesterol and total adiponectin concentrations (Table 2, Figure 1). aSAT was directly associated with 120min glucose, triglycerides, cholesterol and leptin concentrations, insulinogenic index, systolic and diastolic blood pressure, CRP, and total leukocyte count, and inversely with Matsuda index and total adiponectin (Table 2, Figure 1). The strength of associations was stronger for aSAT than those of VAT in all instances, which was supported by the significance of the Wald test (Table 2).

When the sexes were analysed separately, among men aSAT had stronger associations with the majority of cardiometabolic risk markers, with the exception of fasting plasma glucose and systolic blood pressure (Table 3, Figure 2). In women, all the cardiometabolic risk markers were associated only with aSAT, except for TG:HDL ratio which was positively and HDL cholesterol concentrations which were negatively associated with VAT (Table 3, Figure 2). At all instances, the beta estimates for aSAT were stronger than those for VAT (Table 3).

Additional adjustment of height in the above models did not change the results.

In logistic regression models, even though only a small number (12/592) had metabolic syndrome, this was significantly associated with aSAT (OR 2.82, 95% CI 1.83 - 4.35) but not VAT (1.59, 0.85 - 2.99). No associations were observed with prediabetes (aSAT: 1.13, 0.93-1.34; VAT: 1.12, 0.92-1.36).

DISCUSSION

This is the first Indian population-based study of MRI measurements of abdominal fat compartments in apparently healthy, lean native young rural adults. Traditionally, such a population would be considered to have low levels of risk factors for diabetes and cardiovascular disease. However, 30% of them had prediabetes on an OGTT. This was related to poor intrauterine growth and higher maternal glycemia when pregnant with this child (20). Present investigation was to investigate the associations of abdominal fat depots with levels of cardiometabolic risk factors. We found stronger associations of aSAT with glucose-insulin indices, blood pressure, lipids, adipocytokines and inflammatory markers compared to those of VAT. Unlike aSAT, VAT was associated with only a few cardiometabolic risk factors (glucose, blood pressure, lipids), and metabolic syndrome was significantly associated with aSAT (OR 2.82, 95% CI 1.83 - 4.35) but not VAT (1.59, 0.85 - 2.99). In Western populations, VAT is consistently more strongly associated with type 2 diabetes and cardiometabolic risk (6, 21, 22). A recent meta-analysis (23) showed strong association of VAT/aSAT ratio with multiple cardiovascular outcomes including arterial stiffness. In contrast, our study found a stronger association of aSAT with a range of cardiometabolic risk markers than VAT.

The literature describing differential associations of aSAT and VAT with cardiometabolic risk factors in South Asian Indians is heterogeneous. Studies in relatively young (mean age 32y) non-obese North Indian healthy participants and patients with type 2 diabetes, showed an association of aSAT than VAT with cardiometabolic risk factors such as dyslipidaemia,

hypertension, and diabetes (9, 10). Our findings in the relatively younger and leaner rural population align with these reports, reinforcing the significance of aSAT in cardiometabolic risk in Indians. On the other hand, evidence from older South Indians (mean age 42y) with or without diabetes indicates a more prominent role of VAT in relation to metabolic syndrome (11, 12). Thus, age, glycaemic status, and ethnicity seem to influence the adipose tissue distribution and in turn its association with cardiometabolic disease risk in Indians. Migrant healthy South Asians (35 to 50 years, BMI 23 to 30 kg/m^2) show higher amounts of total, subcutaneous and visceral abdominal adipose tissue compared to age- and BMI- matched white Caucasians (24-28), which may explain higher insulin resistance and cardiometabolic disease in South Asians.

Women are known to have larger quantities of subcutaneous fat compared to men who have more visceral fat (29). Sex-specific differences in the amount of aSAT and VAT, and their associations with risk markers are evident within the PMNS study (ESM figure 2). Men showed effects of both aSAT and VAT on their metabolic profile, while in women, aSAT drove the risk. These differences may be explained by variable effects of sex hormones in men and women, which are shown to have effects on body composition, metabolism, and energy homoeostasis (30, 31).

While previous studies (32) have highlighted a direct relationship of VAT to pro-inflammatory cytokines in both Europeans and South Asians, our findings show that aSAT is also metabolically active and is associated with pro-inflammatory markers like leptin, TLC, and CRP, and has an inverse association with adiponectin, an anti-inflammatory adipokine. These results indicate that the associations of aSAT with cardiometabolic risk in relatively young and lean South Asians may be mediated by inflammatory pathways.

We compared the distribution of BMI, aSAT, and VAT in PMNS with other studies of S Asian Indians (native and migrant) aged from 18 to 60 years (ESM Figure 3). The PMNS participants were the youngest (18y) and had the lowest BMI but comparable amounts of aSAT and VAT with other groups (12, 28, 33-35), revealing a thin-fat phenotype. Low BMI represents a low lean mass (low metabolic capacity), and the excess abdominal adiposity represents increased metabolic load. This would suggest excess cardiometabolic risk according to the capacity load model (32, 36). This would explain higher risk of cardiometabolic dysfunction at a young age in Indians. Such a phenotype may be rooted in both the thrifty genotype and thrifty phenotype (intrauterine epigenetic programming) which postulate that nutritional scarcity leads to accumulation of fat which helps tide over energy requirements during crisis, but becomes detrimental in periods of excess (37, 38). Our results in a substantially thin population in a community undergoing rapid transition adds a new dimension to the thinking and invites further mechanistic studies.

SAT and VAT arise from distinct precursors and fetal developmental programs, with early-established SAT providing a relatively metabolically protective storage depot, whereas later-developing VAT is more prone to hypertrophic expansion, inflammation, and long-term cardiometabolic risk following adverse intrauterine exposures (39-41). Our findings of stronger associations of aSAT with cardiometabolic risk than VAT could represent a distinct programming of aSAT due to nutritional, metabolic, and other as yet unknown in-utero exposures or an effect of rapid transition in this population.

Abdominal adipose tissue is anatomically divided into superficial (sSAT), deep (dSAT), and visceral (VAT) compartments, each with distinct structural and metabolic characteristics (32). These compartments exhibit a hierarchical gradient of metabolic risk, with VAT showing the most adverse profile due to its portal drainage, heightened inflammation, lipolysis, and insulin

resistance, dSAT displaying intermediate, VAT-like dysfunction, and sSAT retaining greater adipogenic capacity, insulin sensitivity, and metabolic buffering that confer relative protection against cardiometabolic disease (41, 42). While VAT is consistently linked to adverse metabolic outcomes (in migrant SA and European populations), dSAT has also been implicated due to its greater fatty acid flux and pro-inflammatory potential (43). Our observed association of aSAT with metabolic dysfunction, despite not differentiating sSAT and dSAT, might reflect a predominant contribution from dSAT. While aSAT is often considered metabolically neutral or protective (44), emerging evidence in the adult European population (45) suggests a possible pathogenic role. These findings highlight differences in depot-specific adipose tissue function in different populations which may influence cardiometabolic risk. Histological studies of aSAT (total, sSAT and dSAT) in Europeans and migrant South Asians report larger, hypertrophic adipocytes in South Asians compared to Europeans, suggesting reduced adipose expandability, and heightened inflammation (27, 28, 43). Complementing these morphological differences, multi-omics analyses reveal overlapping pro-inflammatory and lipogenic gene expression in both VAT and aSAT among Indians (43, 46-48), contrasting with Western data where VAT alone drives risk (21, 49). Together, these findings underscore population-specific adipose tissue morphology and molecular programming that may underlie the heightened metabolic susceptibility of aSAT in Indians.

To the best of our knowledge this is the first Indian population-based study in a birth cohort with a substantial number (nearly 600) of abdominal fat measurements by MRI. A range of phenotypic and cardiometabolic risk markers are available in this cohort. Image segmentation and measurement of adipose tissue compartments were done under the supervision of the experts in the field of Imaging. The relatively young age of the participants with a substantial number of prediabetic individuals allowed study of an 'evolving' adiposity phenotype not affected by end-stage metabolic conditions and treatment (reverse causality). Differentiation

between superficial and deep aSAT was not possible, which is a limitation. As this is an observational study causality cannot be established. We have used epidemiological rather than gold standard measures of insulin action and secretion.

In conclusion, contrary to findings in Western populations, we report that the subcutaneous component of abdominal adiposity in young native rural Indians is a stronger driver of high glucose levels, inflammation, and adverse cardiometabolic profiles than the visceral component. Further studies are needed to understand the developmental, molecular, and cellular mechanisms of these differences. Our findings challenge conventional paradigms and suggest the need for age and ethnicity-specific approaches to risk assessment, and targeted life-style and drug interventions.

Declarations:

Ethics approval and consent to participate

The study was approved by local village leaders and the Ethics Committee of the KEM Hospital Research Centre (KEMHRC/VSP/Dir. Off/EC12465). An informed consent form was signed by all participants. Ethical approvals pertaining to this secondary analysis were obtained from KEM: KEMHRC/RVM/EC/1037 and SIU: EC/NEW/IND/2024/MH/0477.

Consent for publication

Not Applicable

Availability of data and materials

The dataset supporting the conclusions of this article is available for additional analyses by applying to the corresponding author with a 200-word plan of analysis. Data sharing is subject to KEM Hospital Research Centre administrative approvals and permission from the Government of India's Health Ministry Screening Committee

Competing interests

The authors declare that they have no competing interests.

Funding

The PMNS was funded by the Wellcome Trust, UK (038128/Z/93, 059609/Z/99, 079877/Z/06/Z, 098575/B/12/Z and 083460/Z/07/Z); the Medical Research Council, UK (MR/J000094/1); and the Department of Biotechnology, Government of India (BT/PR-6870/PID/20/268/2005). Rashmi Prasad has received funding support from VINNOVA (2023-04234) and VR (2021-02623).

Authors' contributions

CSY and CHDF conceptualised the study. RSHW was involved in statistical analysis. RB and WA contributed to MRI image data cleaning and image segmentation. ELT and JDB set up and supervised the MRI image segmentation, and shared the summary statistics for migrant SA

from different UK studies. CSY and RSHW prepared the manuscript. RP and SK were involved in the critical review of the manuscript. All authors were involved in the review of the manuscript, and approved the final version of the manuscript. CSY is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis

Acknowledgements

We thank the participants, collaborators, funding agencies and the Diabetes Unit staff for their contribution towards this study. We would also like to thank the authors for the following cohorts - MASALA-MESA (Alka Kanaya), MolSHARE (Sonia Anand), CURES (RM Anjana) - for sharing the summary statistics plotted in Figure 3.

Table 1: Characteristics of the participants

Measures	Men (n=310)		Women (n=280)	
Age (years)	18.2	(17.9, 18.6)	17.6	(17.2, 18.1)
Height (cm)	169.6	(165.5, 173.7)	157.0	(153.3, 160.7)
Weight (kg)	55.49	(49.39, 62.02)	44.8	(41.3, 49.9)
Body Mass Index (BMI, kg/m^2)	19.0	(17.2, 21.3)	18.7	(16.8, 20.2)
• Underweight (BMI < 18.5)	127	(41.1)	153	(54.4)
• Overweight/Obese (BMI > 25)	28	(9.1)	12	(4.3)
Waist circumference (cm)	71.0	(66.5, 77.5)	67.5	(63.3, 71.8)
Hip circumference (cm)	87.0	(82.3, 92.4)	86.1	(82.0, 89.9)
WHR	0.82	(0.79, 0.85)	0.78	(0.75, 0.81)
Sum of skinfolds (mm)	32.6	(24.0, 52.3)	57.3	(42.3, 79.9)
MRI aSAT (cm^2)	217.6	(152.2, 363.8)	311.2	(219.3, 442.6)
MRI VAT (cm^2)	194.5	(158.5, 242.3)	164.7	(132.0, 204.3)
MRI total abdominal area (cm^2)	408.5	(325.6, 608.8)	473.8	(365.9, 623.9)
MRI aSAT/VAT ratio	1.2	(0.9, 1.8)	1.9	(1.4, 2.7)
Fasting glucose (mmol/l)	5.39	(5.17, 5.61)	5.17	(4.94, 5.33)
30-min glucose (mmol/l)	8.28	(7.56, 9.17)	8.33	(7.50, 9.06)
120-min glucose (mmol/l)	6.11	(5.33, 7.01)	6.33	(5.50, 7.11)
Fasting insulin (pmol/l)	62.5	(45.1, 88.9)	75.0	(57.6, 94.5)
30-min insulin (pmol/l)	552.1	(376.4, 810.6)	675.7	(452.8, 895.4)
120-min insulin (pmol/l)	319.5	(188.9, 485.6)	456.4	(288.9, 671.5)
Impaired fasting glucose (IFG)	88	(28.4)	24	(8.5)
Impaired glucose tolerance (IGT)	13	(4.2)	23	(8.2)
Prediabetes (IFG+IGT)	124	(40)	55	(19.6)
Insulinogenic index	1.70	(1.39, 2.07)	1.69	(1.36, 2.07)
Matsuda index	13.2	(9.46, 19.12)	11.76	(8.81, 15.74)
Disposition Index	4.31	(3.81, 4.83)	4.12	(3.71, 4.57)
Systolic BP (mmHg)	112	(106, 119)	106	(100, 110)
Diastolic BP (mmHg)	58	(53, 64)	61	(57, 65)
Cholesterol (mmol/l)	3.14	(2.79, 3.59)	3.44	(3.03, 3.79)
HDL (mmol/l)	0.98	(0.85, 1.09)	1.09	(0.96, 1.24)
Triglycerides (mmol/l)	0.69	(0.53, 0.86)	0.60	(0.49, 0.75)
Leptin (ng/mL)	2.7	(1.2, 6.7)	15.8	(10.1, 25.1)
Adiponectin (ng/mL)	4.7	(3.7, 5.9)	5.1	(4.0, 6.5)
TLC (10^3/µL)	5.8	(5.1, 6.6)	6.3	(5.6, 7.4)
C-reactive protein	0.08	(0.06, 0.13)	0.07	(0.05, 0.11)

Data is presented as median (25th-75th) or N (%) where appropriate.

Table 2: Associations of MRI measurements with cardiometabolic risk markers

Outcome	aSAT		VAT		Difference b/w coefficients
	β (SE)	p-value	β (SE)	p-value	Z (p-value)
Fasting glucose	0.035 (0.046)	0.447	**0.097 (0.046)**	**0.037**	-0.94 (0.345)
120-minute glucose	**0.137 (0.048)**	**0.004**	-0.008 (0.048)	0.863	**2.14 (0.032)**
Insulinogenic Index	0.022 (0.049)	0.650	-0.029 (0.048)	0.549	0.75 (0.456)
Matsuda Index	**-0.346 (0.044)**	**0.000**	**-0.116 (0.043)**	**0.007**	**-3.74 (0.000)**
Disposition Index	**-0.275 (0.046)**	**0.000**	-0.061 (0.046)	0.183	**-3.29 (0.001)**
Systolic BP	**0.217 (0.045)**	**0.000**	**0.129 (0.045)**	**0.004**	1.39 (0.163)
Diastolic BP	**0.306 (0.045)**	**0.000**	0.010 (0.045)	0.830	**4.70 (0.000)**
Triglycerides	**0.224 (0.045)**	**0.000**	**0.091 (0.045)**	**0.043**	**2.09 (0.037)**
Cholesterol	**0.198 (0.046)**	**0.000**	0.055 (0.046)	0.229	**2.22 (0.026)**
HDL-cholesterol	-0.039 (0.047)	0.400	-0.085 (0.047)	0.070	0.69 (0.490)
LDL-cholesterol	**0.279 (0.046)**	**0.000**	0.028 (0.045)	0.538	**3.90 (0.000)**
TG:HDL-c	**0.197 (0.045)**	**0.000**	**0.112 (0.045)**	**0.014**	1.35 (0.178)
Leptin	**0.694 (0.032)**	**0.000**	**0.091 (0.032)**	**0.004**	**13.50 (0.000)**
Total Adiponectin	**-0.256 (0.046)**	**0.000**	-0.064 (0.045)	0.158	**-2.97 (0.003)**
Total leukocyte count	**0.190 (0.046)**	**0.000**	0.015 (0.046)	0.737	**2.69 (0.007)**
C-reactive protein	**0.153 (0.049)**	**0.002**	-0.009 (0.048)	0.855	**2.36 (0.018)**

Data are presented as beta coefficient (standard error, SE) using multiple linear regression analysis. All variables were converted to standardised residuals before analysis. Difference between the coefficients was calculated using Wald's test and presented as Z statistics (p-value).

Table 3: Associations of MRI measurements with cardiometabolic risk markers separately for sexes.

	Males					Females				
	aSAT		VAT		Difference b/w coefficients	aSAT		VAT		Difference b/w coefficients
Outcome	**β (SE)**	**p-value**	**β (SE)**	**p-value**	**Z (p-value)**	**β (SE)**	**p-value**	**β (SE)**	**p-value**	**Z (p-value)**
Fasting glucose	0.016 (0.051)	0.752	**0.107 (0.051)**	**0.037**	-1.26 (0.207)	0.055 (0.079)	0.488	0.088 (0.079)	0.268	-0.29 (0.769)
120-minute glucose	**0.154 (0.067)**	**0.022**	0.065 (0.067)	0.330	0.95 (0.343)	0.110 (0.069)	0.111	-0.098 (0.068)	0.155	**2.14 (0.032)**
Insulinogenic Index	0.059 (0.069)	0.390	-0.042 (0.069)	0.540	1.04 (0.297)	-0.023 (0.068)	0.739	-0.015 (0.067)	0.822	-0.08 (0.937)
Matsuda Index	**-0.490 (0.058)**	**0.000**	**-0.170 (0.058)**	**0.003**	**-3.92 (0.000)**	**-0.172 (0.064)**	**0.008**	-0.046 (0.063)	0.464	-1.41 (0.158)
Disposition Index	**-0.334 (0.063)**	**0.000**	**-0.135 (0.063)**	**0.033**	-2.23 (0.026)	**-0.200 (0.067)**	**0.003**	0.031 (0.066)	0.641	**-2.45 (0.014)**
Systolic BP	**0.191 (0.069)**	**0.006**	**0.237 (0.070)**	**0.001**	-0.47 (0.639)	**0.235 (0.055)**	**0.000**	0.015 (0.055)	0.792	**2.84 (0.005)**
Diastolic BP	**0.325 (0.073)**	**0.000**	0.035 (0.073)	0.631	**2.82 (0.005)**	**0.284 (0.050)**	**0.000**	-0.019 (0.050)	0.706	**4.25 (0.000)**
Triglycerides	**0.294 (0.066)**	**0.000**	0.119 (0.066)	0.072	1.87 (0.061)	**0.147 (0.061)**	**0.016**	0.056 (0.061)	0.353	1.06 (0.291)
Cholesterol	**0.223 (0.064)**	**0.001**	**0.144 (0.064)**	**0.025**	0.89 (0.376)	**0.164 (0.065)**	**0.012**	-0.041 (0.065)	0.527	**2.24 (0.025)**
HDL-cholesterol	-0.036 (0.068)	0.602	-0.009 (0.068)	0.898	-0.28 (0.781)	-0.049 (0.063)	0.434	**-0.166 (0.063)**	**0.009**	1.30 (0.193)
LDL-cholesterol	**0.379 (0.066)**	**0.000**	0.029 (0.064)	0.645	**3.82 (0.000)**	**0.183 (0.064)**	**0.005**	0.014 (0.064)	0.827	1.86 (0.063)
TG:HDL-c	**0.252 (0.067)**	**0.000**	0.099 (0.067)	0.141	1.60 (0.110)	**0.140 (0.060)**	**0.020**	**0.120 (0.060)**	**0.046**	0.24 (0.812)
Leptin	**0.877 (0.048)**	**0.000**	**0.184 (0.048)**	**0.000**	**10.18 (0.000)**	**0.490 (0.032)**	**0.000**	-0.022 (0.032)	0.495	**11.32 (0.000)**
Total Adiponectin	**-0.267 (0.065)**	**0.000**	**-0.132 (0.063)**	**0.038**	-1.49 (0.136)	**-0.239 (0.066)**	**0.000**	0.011 (0.065)	0.868	**-2.71 (0.007)**
Total leukocyte count	**0.201 (0.063)**	**0.001**	0.033 (0.063)	0.593	1.89 (0.058)	**0.176 (0.068)**	**0.010**	-0.005 (0.068)	0.944	1.89 (0.059)
C-reactive protein	**0.128 (0.064)**	**0.047**	0.040 (0.064)	0.534	0.97 (0.330)	**0.180 (0.074)**	**0.016**	-0.066 (0.074)	0.371	**2.35 (0.019)**

Data are presented as beta coefficient (standard error, SE) using multiple linear regression analysis. All variables were converted to standardised residuals before analysis. Difference between the coefficients was calculated using Wald's test and presented as Z statistics (p-value).

Figure legends

Figure 1. **Associations between VAT, aSAT, and the metabolic profile of the participants adjusted for age and sex.** Figure shows associations (beta estimates) between SAT, VAT and a range of cardiometabolic risk factors. Size of the ribbon is directly proportional to the beta estimates, red represents significant positive associations, blue – significant negative associations, grey – non-significant. Comparison between the beta coefficients of SAT and VAT was performed using Wald test, and significance ($p<0.05$) is denoted by orange star.

Figure 2. Associations between VAT, aSAT, and the metabolic profile of the participants adjusted for age and separately for sexes. Sankey diagram showing the associations (beta estimates) between VAT, aSAT, and the metabolic profile of the participants separately for sexes. Comparison between the beta coefficients of SAT and VAT was performed using Wald test, and significance ($p<0.05$) is denoted by orange star.

ESM Figure 1. STROBE flow diagram of Pune Maternal Nutrition Study. # 590 participants included in analysis were similar to 73 who were excluded, except for 120 min OGTT glucose.

ESM Figure 2. Distribution of aSAT and VAT amount in the men and women of the PMNS.

ESM Figure 3. Distribution of BMI, aSAT, VAT, and aSAT/VAT ratio across South-Asian Indian population (Native + Migrant). Standardised values of BMI, VAT, aSAT, and aSAT/VAT ratio across for given age. Standardised values are calculated as Z scores of the summary statistics between the studies for each variable. Cohorts – native SA (light colour): PMNS, CRISIS, CURES; migrant SA (dark colour): Migrant SA from different UK studies (UK SA 1, UK SA 2), Mediators of Atherosclerosis in South Asians Living in America (MASALA) and Multi-Ethnic Study of Atherosclerosis (MESA), USA; The Molecular Study of Health and Risk in Ethnic Groups (MolSHARE), Canada

References

1. World Health O. Obesity and overweight Geneva: World Health Organization; 2025 [updated 2025/05/07. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. India U. India: Overweight and obesity rising across all ages – from youngest children to adults. 2025 2025/09/11.
3. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–62.
4. Garvey WT. Adiposity-Based Chronic Disease. In: Mechanick JI, Kushner RF, editors. Lifestyle Medicine. Cham: Springer; 2025. p. 11–29.
5. Ganpule-Rao A, Joglekar C, Patkar D, Chinchwadkar M, Bhat D, Lubree H, et al. Associations of trunk fat depots with insulin resistance, beta cell function and glycaemia--a multiple technique study. PLoS One. 2013;8(10):e75391.
6. Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–25.
7. Schoettl T, Fischer IP, Ussar S. Heterogeneity of adipose tissue in development and metabolic function. J Exp Biol. 2018;221(Pt Suppl 1).
8. Iliodromiti S, McLaren J, Ghouri N, Miller MR, Dahlqvist Leinhard O, Linge J, et al. Liver, visceral and subcutaneous fat in men and women of South Asian and white European descent: a systematic review and meta-analysis of new and published data. Diabetologia. 2023;66(1):44–56.
9. Goel K, Misra A, Vikram NK, Poddar P, Gupta N. Subcutaneous abdominal adipose tissue is associated with the metabolic syndrome in Asian Indians independent of intra-abdominal and total body fat. Heart. 2010;96(8):579–83.
10. Misra A, Anoop S, Gulati S, Mani K, Bhatt SP, Pandey RM. Body Fat Patterning, Hepatic Fat and Pancreatic Volume of Non-Obese Asian Indians with Type 2 Diabetes in North India: A Case-Control Study. PLoS One. 2015;10(10):e0140447.
11. Sandeep S, Gokulakrishnan K, Velmurugan K, Deepa M, Mohan V. Visceral & subcutaneous abdominal fat in relation to insulin resistance & metabolic syndrome in non-diabetic south Indians. Indian J Med Res. 2010;131:629–35.
12. Anjana M, Sandeep S, Deepa R, Vimaleswaran KS, Farooq S, Mohan V. Visceral and central abdominal fat and anthropometry in relation to diabetes in Asian Indians. Diabetes Care. 2004;27(12):2948–53.
13. Rao S, Yajnik CS, Kanade A, Fall CH, Margetts BM, Jackson AA, et al. Intake of micronutrient-rich foods in rural Indian mothers is associated with the size of their babies at birth: Pune Maternal Nutrition Study. J Nutr. 2001;131(4):1217–24.
14. Sun J, Xu B, Freeland-Graves J. Automated quantification of abdominal adiposity by magnetic resonance imaging. Am J Hum Biol. 2016;28(6):757–66.
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.
16. Wareham NJ, Phillips DI, Byrne CD, Hales CN. The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med. 1995;12(10):931.
17. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.
18. American Diabetes A. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14–80.

19. International Diabetes F. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation; 2006.
20. Yajnik CS, Bandopadhyay S, Bhalerao A, Bhat DS, Phatak SB, Wagh RH, et al. Poor In Utero Growth, and Reduced β-Cell Compensation and High Fasting Glucose From Childhood, Are Harbingers of Glucose Intolerance in Young Indians. Diabetes Care. 2021;44(12):2747–57.
21. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48.
22. Mao J, Gan S, Gong S, Zhou Q, Yu F, Zhou H, et al. Visceral fat area is more strongly associated with arterial stiffness than abdominal subcutaneous fat area in Chinese patients with type 2 diabetes. Diabetol Metab Syndr. 2024;16(1):123.
23. Emamat H, Jamshidi A, Farhadi A, Ghalandari H, Ghasemi M, Tangestani H. The association between the visceral to subcutaneous abdominal fat ratio and the risk of cardiovascular diseases: a systematic review. BMC Public Health. 2024;24(1):1827.
24. Chowdhury B, Lantz H, Sjostrom L. Computed tomography-determined body composition in relation to cardiovascular risk factors in Indian and matched Swedish males. Metabolism. 1996;45(5):634–44.
25. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84(1):137–44.
26. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001;86(11):5366–71.
27. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG, Grundy SM, et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS One. 2007;2(8):e812.
28. Anand SS, Tarnopolsky MA, Rashid S, Schulze KM, Desai D, Mente A, et al. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One. 2011;6(7):e22112.
29. Bjorntorp P. Fat cell distribution and metabolism. Ann N Y Acad Sci. 1987;499:66–72.
30. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab. 2002;87(10):4522–7.
31. Syme C, Abrahamowicz M, Leonard GT, Perron M, Pitiot A, Qiu X, et al. Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms. Arch Pediatr Adolesc Med. 2008;162(5):453–61.
32. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol. 2007;36(1):220–5.
33. Thomas EL, Parkinson JR, Hyde MJ, Yap IK, Holmes E, Dore CJ, et al. Aberrant adiposity and ectopic lipid deposition characterize the adult phenotype of the preterm infant. Pediatr Res. 2011;70(5):507–12.
34. Mongraw-Chaffin M, Gujral UP, Kanaya AM, Kandula NR, Carr JJ, Anderson CAM. Relation of Ectopic Fat with Atherosclerotic Cardiovascular Disease Risk Score in South Asians Living in the United States (from the Mediators of Atherosclerosis in South Asians Living in America [MASALA] Study). Am J Cardiol. 2018;121(3):315–21.
35. Flowers E, Lin F, Kandula NR, Allison M, Carr JJ, Ding J, et al. Body Composition and Diabetes Risk in South Asians: Findings From the MASALA and MESA Studies. Diabetes Care. 2019;42(5):946–53.

36. Wells JC, Pomeroy E, Walimbe SR, Popkin BM, Yajnik CS. The Elevated Susceptibility to Diabetes in India: An Evolutionary Perspective. Front Public Health. 2016;4:145.
37. Yajnik CS, Fall CH, Coyaji KJ, Hirve SS, Rao S, Barker DJ, et al. Neonatal anthropometry: the thin-fat Indian baby. The Pune Maternal Nutrition Study. Int J Obes Relat Metab Disord. 2003;27(2):173–80.
38. Yajnik CS. Early life origins of the epidemic of the double burden of malnutrition: life can only be understood backwards. Lancet Reg Health Southeast Asia. 2024;28:100453.
39. Desoye G, Herrera E. Adipose tissue development and lipid metabolism in the human fetus: The 2020 perspective focusing on maternal diabetes and obesity. Prog Lipid Res. 2021;81:101082.
40. Orsso CE, Colin-Ramirez E, Field CJ, Madsen KL, Prado CM, Haqq AM. Adipose Tissue Development and Expansion from the Womb to Adolescence: An Overview. Nutrients. 2020;12(9).
41. Lin F, Sul HS. Distinct precursor landscape of subcutaneous and visceral fat in development and aging. Cell Rep. 2026;45(1):116706.
42. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.
43. Marinou K, Hodson L, Vasan SK, Fielding BA, Banerjee R, Brismar K, et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care. 2014;37(3):821–9.
44. Agrawal S, Klarqvist MDR, Diamant N, Stanley TL, Ellinor PT, Mehta NN, et al. BMI-adjusted adipose tissue volumes exhibit depot-specific and divergent associations with cardiometabolic diseases. Nat Commun. 2023;14(1):266.
45. Thanaj M, Basty N, Cule M, Sorokin EP, Whitcher B, Srinivasan R, et al. Changes in abdominal subcutaneous adipose tissue thickness associate with disease and anthropometric factors. Int J Obes (Lond). 2025;49(9):1810–9.
46. Saxena A, Tiwari P, Wahi N, Soni A, Bansiwal RC, Kumar A, et al. Transcriptome profiling reveals association of peripheral adipose tissue pathology with type-2 diabetes in Asian Indians. Adipocyte. 2019;8(1):125–36.
47. Kumar A, Tiwari P, Saxena A, Purwar N, Wahi N, Sharma B, et al. The Transcriptomic Evidence on the Role of Abdominal Visceral vs. Subcutaneous Adipose Tissue in the Pathophysiology of Diabetes in Asian Indians Indicates the Involvement of Both. Biomolecules. 2020;10(9).
48. Saxena A, Mathur N, Tiwari P, Mathur SK. Whole transcriptome RNA-seq reveals key regulatory factors involved in type 2 diabetes pathology in peripheral fat of Asian Indians. Sci Rep. 2021;11(1):10632.
49. Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab. 2020;2(1):97–109.

Figure 1


Fasting glucose
OGTT 120min glucose
Insulinogenic Index
Matsuda Index (ISen)
Systolic BP
Diastolic BP
Triglyceride
Tot Cholesterol
HDL-c
LDL-c
TG:HDL
Leptin
Adiponectin
Total Leukocyte Count
CRP
aSAT
VAT
Positive
Negative
NS
EXPOSURE
OUTCOME

Figure 2


a
b
aSAT
VAT
Fasting glucose
OGTT 120min glucose
Insulinogenic Index
Matsuda Index (ISen)
Systolic BP
Diastolic BP
Triglyceride
Tot Cholesterol
HDL-c
LDL-c
TG:HDL
Leptin
Adiponectin
Total Leukocyte Count
CRP
EXPOSURE
OUTCOME
Positive
Negative
NS

ESM Figure 1


All married non pregnant women in 6 villages
n = 2675
Consented to participate **n = 2466** (92%)
1994- 1996
797 pregnancies enrolled
Live births (n = **762**)
Deaths: n = 40
2013- 2014
18 year follow up
Of 722 alive, followed up **n = 663** (92%)
2013- 2014
18 year follow up
Of 663, Abdominal MRI done on **n = 599**
#
Scan excluded due to poor image quality, **n = 8**
Participant having MODY diabetes excluded , **n = 1**
Participants included in analysis, **n = 590**

ESM Figure 2


a
MRI VAT area in men and women
density
0.008
0.006
0.004
0.002
0.000
100
200
300
400
b
MRI aSAT area in men and women
density
0.004
0.003
0.002
0.001
0.000
0
250
500
750
1000
c
MRI Total abd area in men and women
density
0.003
0.002
0.001
0.000
0
250
500
750
1000
Men
Women

ESM Figure 3


MALES
FEMALES
BMI
SAT
VAT
SAT.VAT_Ratio
PMNS (18y)
UK.SA1 (23y)
UK.SA2 (24y)
MolSHARE (37y)
CRISIS (42y)
CURES (45y)
MASALA (55y)
-1
0
1
2
Standardized Mean (Z-score)